Chugai Pharmaceutical Co.... (CHGCF)
OTC: CHGCF
· Real-Time Price · USD
39.99
-3.97 (-9.03%)
At close: Aug 15, 2025, 2:46 PM
43.96
9.93%
After-hours: Aug 13, 2025, 08:00 PM EDT
Chugai Pharmaceutical Income Statement
Financials in JPY. Fiscal
year is
January - December.
| Fiscal Year | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 315.91B | 236.95B | 273.81B | 257.9B | 267.42B | 312.24B | 438.5B | 225.28B | 235.61B | 360.56B | 322.27B | 287.26B | 221.41B | 168.82B |
Cost of Revenue | 87.94B | 72.95B | 92.06B | 78.26B | 91.66B | 151.33B | 212.91B | 69.1B | 79.82B | 114.42B | 110.56B | 104.19B | 68.06B | 55.34B |
Gross Profit | 227.97B | 164B | 181.75B | 179.64B | 175.75B | 160.91B | 225.59B | 156.19B | 155.79B | 246.13B | 211.71B | 183.07B | 153.35B | 113.48B |
Operating Income | 158.32B | 101.55B | 114.34B | 106.69B | 112.61B | 98.3B | 149.47B | 96.89B | 99.94B | 187.01B | 139.06B | 122.16B | 96.71B | 63.97B |
Interest Income | 480M | 15M | n/a | n/a | 1.39B | 1.37B | n/a | n/a | 788M | 1.61B | n/a | n/a | n/a | n/a |
Pretax Income | 158.8B | 99.89B | 122.69B | 107.47B | 113.99B | 99.66B | 149.22B | 95.03B | 100.71B | 186.21B | 138.44B | 119.69B | 97.02B | 64.24B |
Net Income | 111.86B | 74.4B | 91.21B | 77.57B | 83.19B | 73.5B | 102.48B | 67.8B | 72.38B | 131.78B | 98.84B | 86.02B | 70.73B | 47.41B |
Selling & General & Admin | 27.32B | 21.18B | 25.56B | 27.54B | 33.26B | 21.02B | 30.88B | 22.59B | 22.03B | 25.26B | 34.84B | 24.71B | 23.08B | 19.79B |
Research & Development | 42.94B | 41.27B | 41.86B | 45.57B | 44.57B | 42.87B | 45.23B | 36.71B | 33.82B | 33.87B | 37.81B | 36.2B | 33.56B | 29.73B |
Other Expenses | -603M | n/a | n/a | n/a | n/a | n/a | 267M | n/a | n/a | n/a | 259M | n/a | -4M | n/a |
Operating Expenses | 69.65B | 62.45B | 67.42B | 72.95B | 63.14B | 62.62B | 76.11B | 59.3B | 55.85B | 59.12B | 72.65B | 60.91B | 56.64B | 49.51B |
Interest Expense | n/a | n/a | 8M | 7M | 9M | 2M | 526M | 15M | 15M | 14M | 957M | 12M | 12M | 12M |
Selling & Marketing Expenses | 27.32B | 22.59B | 30.76B | 27.54B | 33.26B | 21.02B | 23.04B | 18.83B | 18.5B | 16.79B | 24.35B | 18.46B | 17.91B | 15.87B |
Cost & Expenses | 157.59B | 135.4B | 159.47B | 151.21B | 154.8B | 213.94B | 289.02B | 128.4B | 135.67B | 173.55B | 183.2B | 165.11B | 124.7B | 104.85B |
Income Tax Expense | 46.94B | 25.49B | 31.48B | 29.9B | 30.8B | 26.16B | 46.74B | 27.23B | 28.34B | 54.43B | 39.6B | 33.67B | 26.29B | 16.83B |
Shares Outstanding (Basic) | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.64B | 1.64B | 1.64B | 1.64B | 1.64B | 1.64B | 1.64B |
Shares Outstanding (Diluted) | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.65B | 1.64B | 1.65B | 1.65B | 1.65B |
EPS (Basic) | 67.97 | 45.22 | 55.43 | 47.15 | 50.57 | 44.68 | 62.30 | 41.21 | 44.00 | 80.14 | 60.11 | 52.31 | 43.02 | 28.84 |
EPS (Diluted) | 67.97 | 45.21 | 55.43 | 47.14 | 50.56 | 44.67 | 62.28 | 41.21 | 43.99 | 80.09 | 60.08 | 52.28 | 42.99 | 28.82 |
EBITDA | 158.32B | 99.87B | 122.7B | 107.48B | 114B | 99.66B | 149.23B | 95.05B | 100.73B | 186.22B | 138.45B | 119.7B | 97.03B | 64.25B |
EBIT | 158.32B | 99.87B | 122.7B | 107.48B | 114B | 99.66B | 149.23B | 95.05B | 100.73B | 186.22B | 138.45B | 119.7B | 97.03B | 64.25B |
Depreciation & Amortization | n/a | 400M | 1.6B | 300M | 400M | 500M | 600M | 500M | 300M | 300M | 2.1B | 400M | 1.2B | 300M |